Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3186) 3186
Publication (206) 206
Book Review (39) 39
Newsletter (25) 25
Book Chapter (7) 7
Magazine Article (7) 7
Newspaper Article (7) 7
Trade Publication Article (2) 2
Book / eBook (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2639) 2639
enoxaparin (1968) 1968
female (1600) 1600
male (1540) 1540
index medicus (1384) 1384
anticoagulants - administration & dosage (1204) 1204
enoxaparin - administration & dosage (1183) 1183
middle aged (1107) 1107
aged (1029) 1029
anticoagulants - therapeutic use (874) 874
adult (805) 805
prevention (791) 791
venous thromboembolism (786) 786
enoxaparin - therapeutic use (754) 754
molecular-weight heparin (749) 749
treatment outcome (693) 693
anticoagulants - adverse effects (692) 692
anticoagulants (689) 689
hematology (618) 618
thromboembolism (578) 578
enoxaparin - adverse effects (557) 557
unfractionated heparin (546) 546
surgery (533) 533
peripheral vascular disease (529) 529
risk factors (528) 528
heparin (506) 506
venous thromboembolism - prevention & control (469) 469
deep-vein thrombosis (466) 466
thrombosis (441) 441
thromboprophylaxis (440) 440
drug therapy (414) 414
pharmacology & pharmacy (410) 410
aged, 80 and over (397) 397
hemorrhage - chemically induced (385) 385
venous thrombosis - prevention & control (372) 372
cardiac & cardiovascular systems (365) 365
prophylaxis (363) 363
rivaroxaban (354) 354
drug administration schedule (348) 348
prospective studies (333) 333
administration, oral (332) 332
dosage and administration (331) 331
heparin, low-molecular-weight - administration & dosage (331) 331
fibrinolytic agents - administration & dosage (329) 329
retrospective studies (328) 328
postoperative complications - prevention & control (321) 321
dose-response relationship, drug (313) 313
medicine, general & internal (309) 309
warfarin (299) 299
time factors (293) 293
thromboembolism - prevention & control (290) 290
heparin - administration & dosage (279) 279
heparin, low-molecular-weight - therapeutic use (269) 269
factor xa inhibitors (258) 258
injections, subcutaneous (257) 257
fibrinolytic agents - therapeutic use (256) 256
abridged index medicus (250) 250
pharmacokinetics (250) 250
medicine & public health (244) 244
anticoagulation (240) 240
therapy (235) 235
double-blind (230) 230
risk (230) 230
care and treatment (228) 228
venous thrombosis (226) 226
safety (225) 225
heparin - therapeutic use (224) 224
low-molecular-weight heparin (222) 222
health aspects (221) 221
analysis (220) 220
anticoagulants - pharmacology (218) 218
animals (211) 211
research (208) 208
venous thromboembolism - etiology (208) 208
venous thrombosis - drug therapy (205) 205
double-blind method (204) 204
enoxaparin - pharmacology (201) 201
pulmonary-embolism (199) 199
adolescent (196) 196
trial (195) 195
drug therapy, combination (193) 193
risk assessment (193) 193
pulmonary embolism (192) 192
anticoagulants - pharmacokinetics (188) 188
follow-up studies (187) 187
randomized controlled trials as topic (187) 187
dabigatran (182) 182
management (177) 177
complications and side effects (176) 176
fondaparinux (174) 174
pregnancy (171) 171
heparin - adverse effects (169) 169
dabigatran etexilate (163) 163
fibrinolytic agents - adverse effects (163) 163
low molecular weight heparin (163) 163
heparin, low-molecular-weight - adverse effects (161) 161
myocardial infarction - drug therapy (159) 159
acute coronary syndromes (158) 158
mortality (157) 157
venous thrombosis - etiology (156) 156
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3042) 3042
German (51) 51
Spanish (36) 36
Russian (32) 32
French (27) 27
Italian (7) 7
Norwegian (6) 6
Chinese (4) 4
Danish (4) 4
Polish (4) 4
Ukrainian (4) 4
Japanese (3) 3
Czech (2) 2
Korean (2) 2
Portuguese (2) 2
Serbian (2) 2
Arabic (1) 1
Bulgarian (1) 1
Hungarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction
by Van De Werf, Frans J and Assessment Safety Efficacy New Thr and Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Uppsala universitet and Institutionen för medicinska vetenskaper
The Lancet, ISSN 0140-6736, 08/2001, Volume 358, Issue 9282, pp. 605 - 613
Current fibrinolytic therapies fail to achieve optimum reperfusion in many patients. Low-molecular-weight heparins and platelet glycoprotein IIb/IIIa... 
MEDICINE, GENERAL & INTERNAL | THROMBOLYSIS | Recurrence | Humans | Middle Aged | Heparin - administration & dosage | Male | Tissue Plasminogen Activator - administration & dosage | Treatment Outcome | Chi-Square Distribution | Enoxaparin - administration & dosage | Immunoglobulin Fab Fragments - administration & dosage | Injections | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Platelet Aggregation Inhibitors - administration & dosage | Survival Analysis | Female | Aged | Fibrinolytic Agents - administration & dosage | Drug Therapy, Combination | Dosage and administration | Thrombolytic drugs | Research | Tenecteplase | Drug therapy | Heart attack | Prevention | Evaluation | Ischemia | Enoxaparin | Reperfusion (Physiology) | Drug therapy, Combination | Heparin | Health aspects | Clinical trials | Heart attacks | Myocardial infarction | Coagulation | Hemorrhage | Bleeding | Infusion | Randomization | Reperfusion | Motivation | Blood platelets | Safety | Heparins | Anticoagulants | Stroke | Effectiveness | Complications | Mortality | Glycoprotein | Pharmacology | Patients | Trauma | Molecular chains | Studies | Fibrin | Monoclonal antibodies | Infarction | Heparin/administration & dosage | Medical and Health Sciences | Medicin och hälsovetenskap | Platelet Aggregation Inhibitors/administration & dosage | MEDICINE | Antibodies; Monoclonal/administration & dosage | Myocardial Infarction/drug therapy | Enoxaparin/administration & dosage | Tissue Plasminogen Activator/administration & dosage | Fibrinolytic Agents/administration & dosage | MEDICIN | Immunoglobulins; Fab/administration & dosage | Drug Therapy; Combination | Research Support; Non-U.S. Gov't
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism
by Weitz, Jeffrey I and Lensing, Anthonie W.A and Prins, Martin H and Bauersachs, Rupert and Beyer-Westendorf, Jan and Bounameaux, Henri and Brighton, Timothy A and Cohen, Alexander T and Davidson, Bruce L and Decousus, Hervé and Freitas, Maria C.S and Holberg, Gerlind and Kakkar, Ajay K and Haskell, Lloyd and van Bellen, Bonno and Pap, Akos F and Berkowitz, Scott D and Verhamme, Peter and Wells, Philip S and Prandoni, Paolo and EINSTEIN CHOICE Investigators
The New England Journal of Medicine, ISSN 0028-4793, 03/2017, Volume 376, Issue 13, pp. 1211 - 1222
In this study involving nearly 3400 patients with venous thromboembolism, both prophylactic and therapeutic doses of rivaroxaban were superior to aspirin in... 
LONG-TERM | ENOXAPARIN | DEFINITION | MEDICINE, GENERAL & INTERNAL | INTENSITY WARFARIN THERAPY | VTE | ARTHROPLASTY | DISEASE | PREVENTION | THROMBOPROPHYLAXIS | Venous Thromboembolism - mortality | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Secondary Prevention | Rivaroxaban - administration & dosage | Aspirin - administration & dosage | Factor Xa Inhibitors - administration & dosage | Venous Thromboembolism - prevention & control | Rivaroxaban - adverse effects | Aspirin - adverse effects | Factor Xa Inhibitors - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Intention to Treat Analysis | Adult | Female | Aged | Hemorrhage - chemically induced | Platelet Aggregation Inhibitors - adverse effects | Rivaroxaban | Care and treatment | Aspirin | Venous thrombosis | Dosage and administration | Diagnosis | Fees & charges | Anticoagulants | Stroke | Heart attacks | Embolisms | Committees | Joint surgery | Thrombosis | Patients | Bleeding | Risk factors | Studies | Prevention | Motivation | Thromboembolism | Health risk assessment | Pharmaceuticals | Veins & arteries | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial
by Kakkar, Ajay K, Prof and Brenner, Benjamin, Prof and Dahl, Ola E, MD and Eriksson, Bengt I, MD and Mouret, Patrick, MD and Muntz, Jim, MD and Soglian, Andrea G, MD and Pap, Ákos F and Misselwitz, Frank, MD and Haas, Sylvia, Prof and RECORD2 Investigators and Institutionen för kliniska vetenskaper, sektionen för anestesi, biomaterial och ortopedi and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Anesthesiology, Biomaterials and Orthopaedics and Sahlgrenska Academy
Lancet, The, ISSN 0140-6736, 2008, Volume 372, Issue 9632, pp. 31 - 39
Summary Background The risk of venous thromboembolism is high after total hip arthroplasty and could persist after hospital discharge. Our aim was to compare... 
Internal Medicine | WEIGHT HEPARIN-PROPHYLAXIS | MEDICINE, GENERAL & INTERNAL | PLACEBO | FACTOR-XA INHIBITOR | ORTHOPEDIC-SURGERY | KNEE REPLACEMENT | BAY-59-7939 | THROMBOSIS | PROLONGED THROMBOPROPHYLAXIS | TIME-COURSE | DALTEPARIN | Thiophenes - therapeutic use | Double-Blind Method | Drug Administration Schedule | Thiophenes - adverse effects | Humans | Middle Aged | Morpholines - administration & dosage | Arthroplasty, Replacement, Hip | Male | Thiophenes - administration & dosage | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Fibrinolytic Agents - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Fibrinolytic Agents - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Fibrinolytic Agents - administration & dosage | Morpholines - adverse effects | Morpholines - therapeutic use | Health care | Medical imaging | Hospitals | Protease inhibitors | Surgery | Tomography | Joint surgery | Drug therapy | Patients | Veins & arteries | Index Medicus | Abridged Index Medicus | Thiophenes/administration & dosage/adverse effects/therapeutic use | use | Arthroplasty | Replacement | Venous Thromboembolism/prevention & control | Morpholines/administration & dosage/adverse effects/therapeutic use | Kirurgi | Hip | 80 and over | Enoxaparin/administration & dosage/adverse effects/therapeutic use | Fibrinolytic Agents/administration & dosage/adverse effects/therapeutic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Risk of major bleeding in different indications for new oral anticoagulants: Insights from a meta-analysis of approved dosages from 50 randomized trials
by Sardar, Partha and Chatterjee, Saurav and Lavie, Carl J and Giri, Jay S and Ghosh, Joydeep and Mukherjee, Debabrata and Lip, Gregory Y.H
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Abstract Background A meta-analysis was performed to evaluate the risk of major bleeding with the use of New Oral Anticoagulants (NOACs). Methods Randomized... 
Cardiovascular | Rivaroxaban | Dabigatran | New oral anticoagulants | Bleeding | Apixaban | Meta-analysis | ENOXAPARIN | CARDIAC & CARDIOVASCULAR SYSTEMS | PREVENTION | ATRIAL-FIBRILLATION | REVERSAL | WARFARIN | THROMBOPROPHYLAXIS | Thiophenes - adverse effects | Humans | Risk | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Thiophenes - administration & dosage | Thiazoles - adverse effects | Factor Xa Inhibitors - administration & dosage | Pyridones - administration & dosage | Benzamides - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Benzamides - adverse effects | Morpholines - adverse effects | Pyrazoles - adverse effects | Azepines - adverse effects | beta-Alanine - adverse effects | Pyridines - administration & dosage | Administration, Oral | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Randomized Controlled Trials as Topic | Pyrazoles - administration & dosage | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Hemorrhage - chemically induced | Azepines - administration & dosage | Pyridones - adverse effects | Anticoagulants (Medicine)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty - A meta-analysis
by Sorrel E. Wolowacz and Neil S. Roskell and Jonathan M. Plumb and Joseph A. Caprini and Bengt I. Eriksson and Institutionen för kliniska vetenskaper, sektionen för anestesi, biomaterial och ortopedi and Sahlgrenska akademin and Göteborgs universitet and Gothenburg University and Institute of Clinical Sciences, Section for Anesthesiology, Biomaterials and Orthopaedics and Sahlgrenska Academy
Thrombosis and Haemostasis, ISSN 0340-6245, 01/2009, Volume 101, Issue 1, pp. 77 - 85
Dabigatran etexilate has been investigated in three phase III trials for the prevention of venous thromboembolism (VTE). Health technology assessment agencies... 
anticoagulants | thrombosis | prophylaxis | Embolism | Meta-analysis | Anticoagulants | Thrombosis | Prophylaxis | ENOXAPARIN | meta-analysis | RANDOMIZED-TRIAL | REPLACEMENT | ORTHOPEDIC-SURGERY | MOLECULAR-WEIGHT HEPARIN | THROMBOSIS PROPHYLAXIS | US HOSPITALS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | UNFRACTIONATED HEPARIN | REGISTRY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Arthroplasty, Replacement, Knee - adverse effects | Humans | Dabigatran | Enoxaparin - therapeutic use | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Clinical Trials, Phase III as Topic | Enoxaparin - administration & dosage | Pyridines - adverse effects | Benzimidazoles - administration & dosage | Benzimidazoles - adverse effects | Benzimidazoles - therapeutic use | Pyridines - therapeutic use | Pyridines - administration & dosage | Drug Administration Schedule | Risk Assessment | Administration, Oral | Anticoagulants - therapeutic use | Treatment Outcome | Anticoagulants - adverse effects | Arthroplasty, Replacement, Hip - adverse effects | Venous Thromboembolism - etiology | Hemorrhage - chemically induced | Administration | Phase III as Topic | Benzimidazoles/administration & dosage/adverse effects/therapeutic use | Pyridines/administration & dosage/adverse effects/therapeutic use | Arthroplasty | Replacement | Oral | Clinical Trials | Kirurgi | Knee/adverse effects | Hemorrhage/chemically induced | Venous Thromboembolism/etiology/mortality/prevention & control | Hip/adverse effects | Anticoagulants/administration & dosage/adverse effects/therapeutic use | Surgery | Enoxaparin/administration & dosage/adverse effects/therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II): A randomised, double-blind, non-inferiority trial
by Eriksson, Bengt I and Dahl, Ola E and Huo, Michael H and Kurth, Andreas A and Hantel, Stefan and Hermansson, Karin and Schnee, Janet M and Friedman, Richard J and RE-NOVATE Il Study Grp and RE-NOVATE II Study Group and for the RE-NOVATE II Study Group and Sahlgrenska akademin and Institute of Clinical Sciences, Section for Anesthesiology, Biomaterials and Orthopaedics, Department of Orthopaedics and Göteborgs universitet and Gothenburg University and Institutionen för kliniska vetenskaper, sektionen för anestesi, biomaterial och ortopedi, Avdelningen för ortopedi and Sahlgrenska Academy
Thrombosis and Haemostasis, ISSN 0340-6245, 04/2011, Volume 105, Issue 4, pp. 721 - 729
This trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in... 
Dabigatran etexilate | Oral anticoagulant | Total hip arthroplasty | Venous thromboembolism | Prophylaxis | SURGERY | DIRECT THROMBIN INHIBITOR | FONDAPARINUX | oral anticoagulant | PREVENTION | DEEP-VEIN THROMBOSIS | prophylaxis | total hip arthroplasty | KNEE REPLACEMENT | venous thromboembolism | MOLECULAR-WEIGHT HEPARIN | ETEXILATE | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | Venous Thromboembolism - mortality | Anticoagulants - administration & dosage | Humans | Middle Aged | Male | Antithrombins - administration & dosage | Dabigatran | Enoxaparin - adverse effects | Venous Thromboembolism - prevention & control | Enoxaparin - administration & dosage | Benzimidazoles - administration & dosage | Hemorrhage - etiology | Injections, Subcutaneous | Female | Venous Thrombosis - prevention & control | Benzimidazoles - adverse effects | beta-Alanine - analogs & derivatives | Postoperative Complications | beta-Alanine - adverse effects | Double-Blind Method | Administration, Oral | Venous Thrombosis - mortality | beta-Alanine - administration & dosage | Anticoagulants - adverse effects | Venous Thrombosis - etiology | Venous Thromboembolism - etiology | Antithrombins - adverse effects | Survival Analysis | Arthroplasty, Replacement, Hip - mortality | Aged | Benzimidazoles | Venous Thrombosis | Oral | Hemorrhage | Antithrombins | Venous Thromboembolism | administration & dosage | Surgery | beta-Alanine | Administration | Anticoagulants | Subcutaneous | Enoxaparin | Arthroplasty | Replacement | prevention & control | Kirurgi | Hip | etiology | Injections | analogs & derivatives | adverse effects | mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
by Mega, Jessica L and Braunwald, Eugene and Wiviott, Stephen D and Bassand, Jean-Pierre and Bhatt, Deepak L and Bode, Christoph and Burton, Paul and Cohen, Marc and Cook-Bruns, Nancy and Fox, Keith A.A and Goto, Shinya and Murphy, Sabina A and Plotnikov, Alexei N and Schneider, David and Sun, Xiang and Verheugt, Freek W.A and Gibson, C. Michael and ATLAS ACS 2-TIMI 51 Investigators and ATLAS ACS 2–TIMI 51 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 1, pp. 9 - 19
In patients with acute coronary syndromes, low doses of rivaroxaban were effective in reducing the primary end point of death from cardiovascular causes,... 
ENOXAPARIN | MEDICINE, GENERAL & INTERNAL | PLACEBO | EVENTS | MYOCARDIAL-INFARCTION | SAFETY | DOUBLE-BLIND | THROMBOPROPHYLAXIS | APIXABAN | FACTOR XA INHIBITOR | ANTIPLATELET THERAPY | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hemorrhage - mortality | Male | Secondary Prevention | Thiophenes - administration & dosage | Incidence | Rivaroxaban | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Drug Administration Schedule | Morpholines - administration & dosage | Kaplan-Meier Estimate | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Acute Coronary Syndrome - drug therapy | Intracranial Hemorrhages - chemically induced | Aged | Hemorrhage - chemically induced | Drugs | Dose-response relationship (Biochemistry) | Dosage and administration | Product/Service Evaluations | Drug therapy | Coronary heart disease | Myocardial infarction | Cerebral infarction | Anticoagulants | Heart attacks | Arteriosclerosis | Coronary artery | Cardiovascular disease | Death | Angina pectoris | Hemorrhage | Thrombosis | Bleeding
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study
by Buller, Harry R and Lensing, Anthonie W. A and Prins, Martin H and Agnelli, Giancarlo and Cohen, Alexander and Gallus, Alexander S and Misselwitz, Frank and Raskob, Gary and Schellong, Sebastian and Segers, Annelise and Einstein DVT Dose-Ranging Study In and Einstein-DVT Dose-Ranging Study investigators
Blood, ISSN 0006-4971, 2008, Volume 112, Issue 6, pp. 2242 - 2247
We performed a randomized dose-ranging study, double-blind for rivaroxaban doses and open-label for the comparator (low-molecular-weight heparin followed by... 
ENOXAPARIN | FONDAPARINUX | PHARMACOKINETICS | PULMONARY-EMBOLISM | ARTHROPLASTY | VENOUS THROMBOSIS | PHASE-II EVALUATION | INITIAL TREATMENT | THROMBOPROPHYLAXIS | HEPARIN | HEMATOLOGY | Acute Disease | Double-Blind Method | Venous Thrombosis - drug therapy | Humans | Middle Aged | Morpholines - administration & dosage | Venous Thrombosis - diagnostic imaging | Antithrombin III - administration & dosage | Male | Treatment Outcome | Thiophenes - administration & dosage | Dose-Response Relationship, Drug | Rivaroxaban | Drug-Related Side Effects and Adverse Reactions | Ultrasonography | Aged, 80 and over | Adult | Female | Aged | Hemorrhage - chemically induced | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights